APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic Biguanides

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antidiabetic Biguanides Market Outlook and Growth Opportunities 2026

20 December 2025195 pages

Choose your research edition.

Industry ResearchAntidiabetic Biguanides Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic Biguanides Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Antidiabetic Biguanides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic Biguanides Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic Biguanides Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antidiabetic Biguanides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antidiabetic Biguanides market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antidiabetic Biguanides market include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic Biguanides market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic Biguanides and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic Biguanides sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic Biguanides market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic Biguanides Segment by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Novo Nordisk

Servier Laboratories

AstraZeneca

GlaxoSmithKline

Pfizer

Eli Lilly

Merck & Co

Sanofi

Takeda Pharmaceuticals

Antidiabetic Biguanides Segment by Type

Metformin IR

Metformin SR

Antidiabetic Biguanides Segment by Application

Hospitals

Clinics

Other

Antidiabetic Biguanides Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antidiabetic Biguanides status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antidiabetic Biguanides market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antidiabetic Biguanides significant trends, drivers, influence factors in global and regions.

6. To analyze Antidiabetic Biguanides competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Biguanides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Biguanides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Biguanides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic Biguanides market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antidiabetic Biguanides industry.

Chapter 3: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antidiabetic Biguanides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antidiabetic Biguanides in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic Biguanides Industry Trends Table 2. Antidiabetic Biguanides Industry Drivers Table 3. Antidiabetic Biguanides Industry Opportunities and Challenges Table 4. Antidiabetic Biguanides Industry Restraints Table 5. Global Antidiabetic Biguanides Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antidiabetic Biguanides Revenue Share by Company (2021-2026) Table 7. Global Antidiabetic Biguanides Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antidiabetic Biguanides Sales Volume Share by Company (2021-2026) Table 9. Global Antidiabetic Biguanides Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antidiabetic Biguanides Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antidiabetic Biguanides Key Company Manufacturing Base & Headquarters Table 12. Global Antidiabetic Biguanides Company, Product Type & Application Table 13. Global Antidiabetic Biguanides Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic Biguanides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Metformin IR Table 18. Significant Companies of Metformin SR Table 19. Global Antidiabetic Biguanides Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antidiabetic Biguanides Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Antidiabetic Biguanides Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Antidiabetic Biguanides Sales Volume Share by Type (2021-2026) Table 23. Global Antidiabetic Biguanides Sales Volume Share by Type (2027-2032) Table 24. Global Antidiabetic Biguanides Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antidiabetic Biguanides Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antidiabetic Biguanides Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antidiabetic Biguanides Sales Value Share by Type (2021-2026) Table 28. Global Antidiabetic Biguanides Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Other Table 32. Global Antidiabetic Biguanides Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Antidiabetic Biguanides Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Antidiabetic Biguanides Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Antidiabetic Biguanides Sales Volume Share by Application (2021-2026) Table 36. Global Antidiabetic Biguanides Sales Volume Share by Application (2027-2032) Table 37. Global Antidiabetic Biguanides Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Antidiabetic Biguanides Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Antidiabetic Biguanides Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Antidiabetic Biguanides Sales Value Share by Application (2021-2026) Table 41. Global Antidiabetic Biguanides Sales Value Share by Application (2027-2032) Table 42. Global Antidiabetic Biguanides Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Antidiabetic Biguanides Sales by Region (2021-2026) & (K Units) Table 44. Global Antidiabetic Biguanides Sales Market Share by Region (2021-2026) Table 45. Global Antidiabetic Biguanides Sales by Region (2027-2032) & (K Units) Table 46. Global Antidiabetic Biguanides Sales Market Share by Region (2027-2032) Table 47. Global Antidiabetic Biguanides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antidiabetic Biguanides Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Antidiabetic Biguanides Sales Value Share by Region (2021-2026) Table 50. Global Antidiabetic Biguanides Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Antidiabetic Biguanides Sales Value Share by Region (2027-2032) Table 52. Global Antidiabetic Biguanides Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Antidiabetic Biguanides Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Antidiabetic Biguanides Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 57. Global Antidiabetic Biguanides Sales Market Share by Country (2021-2026) Table 58. Global Antidiabetic Biguanides Sales by Country (2027-2032) & (K Units) Table 59. Global Antidiabetic Biguanides Sales Market Share by Country (2027-2032) Table 60. Global Antidiabetic Biguanides Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Antidiabetic Biguanides Sales Value Market Share by Country (2021-2026) Table 62. Global Antidiabetic Biguanides Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Antidiabetic Biguanides Sales Value Market Share by Country (2027-2032) Table 64. Boehringer Ingelheim Company Information Table 65. Boehringer Ingelheim Business Overview Table 66. Boehringer Ingelheim Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio Table 68. Boehringer Ingelheim Recent Development Table 69. Bristol-Myers Squibb Company Information Table 70. Bristol-Myers Squibb Business Overview Table 71. Bristol-Myers Squibb Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio Table 73. Bristol-Myers Squibb Recent Development Table 74. Novo Nordisk Company Information Table 75. Novo Nordisk Business Overview Table 76. Novo Nordisk Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Novo Nordisk Antidiabetic Biguanides Product Portfolio Table 78. Novo Nordisk Recent Development Table 79. Servier Laboratories Company Information Table 80. Servier Laboratories Business Overview Table 81. Servier Laboratories Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Servier Laboratories Antidiabetic Biguanides Product Portfolio Table 83. Servier Laboratories Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. AstraZeneca Antidiabetic Biguanides Product Portfolio Table 88. AstraZeneca Recent Development Table 89. GlaxoSmithKline Company Information Table 90. GlaxoSmithKline Business Overview Table 91. GlaxoSmithKline Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. GlaxoSmithKline Antidiabetic Biguanides Product Portfolio Table 93. GlaxoSmithKline Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Pfizer Antidiabetic Biguanides Product Portfolio Table 98. Pfizer Recent Development Table 99. Eli Lilly Company Information Table 100. Eli Lilly Business Overview Table 101. Eli Lilly Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Eli Lilly Antidiabetic Biguanides Product Portfolio Table 103. Eli Lilly Recent Development Table 104. Merck & Co Company Information Table 105. Merck & Co Business Overview Table 106. Merck & Co Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Merck & Co Antidiabetic Biguanides Product Portfolio Table 108. Merck & Co Recent Development Table 109. Sanofi Company Information Table 110. Sanofi Business Overview Table 111. Sanofi Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Sanofi Antidiabetic Biguanides Product Portfolio Table 113. Sanofi Recent Development Table 114. Takeda Pharmaceuticals Company Information Table 115. Takeda Pharmaceuticals Business Overview Table 116. Takeda Pharmaceuticals Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio Table 118. Takeda Pharmaceuticals Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Antidiabetic Biguanides Distributors List Table 122. Antidiabetic Biguanides Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Antidiabetic Biguanides Product Image Figure 2. Global Antidiabetic Biguanides Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic Biguanides Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic Biguanides Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic Biguanides Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antidiabetic Biguanides Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Metformin IR Image Figure 10. Metformin SR Image Figure 11. Global Antidiabetic Biguanides Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antidiabetic Biguanides Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antidiabetic Biguanides Sales Volume Share by Type (2021-2032) Figure 14. Global Antidiabetic Biguanides Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antidiabetic Biguanides Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antidiabetic Biguanides Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Other Image Figure 20. Global Antidiabetic Biguanides Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Antidiabetic Biguanides Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Antidiabetic Biguanides Sales Volume Share by Application (2021-2032) Figure 23. Global Antidiabetic Biguanides Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Antidiabetic Biguanides Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Antidiabetic Biguanides Sales Value Share by Application (2021-2032) Figure 26. Global Antidiabetic Biguanides Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Antidiabetic Biguanides Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Antidiabetic Biguanides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Antidiabetic Biguanides Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Antidiabetic Biguanides Sales Value (2021-2032) & (US$ Million) Figure 31. North America Antidiabetic Biguanides Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Antidiabetic Biguanides Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Antidiabetic Biguanides Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Antidiabetic Biguanides Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Antidiabetic Biguanides Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Antidiabetic Biguanides Sales Value (2021-2032) & (US$ Million) Figure 37. South America Antidiabetic Biguanides Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Antidiabetic Biguanides Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Antidiabetic Biguanides Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Antidiabetic Biguanides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Antidiabetic Biguanides Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Antidiabetic Biguanides Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Metformin IR
  • Metformin SR
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novo Nordisk
  • Servier Laboratories
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck & Co
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antidiabetic Biguanides Sales Value (2021-2032)
  4. 1.2.2 Global Antidiabetic Biguanides Sales Volume (2021-2032)
  5. 1.2.3 Global Antidiabetic Biguanides Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antidiabetic Biguanides Market Dynamics
  1. 2.1 Antidiabetic Biguanides Industry Trends
  2. 2.2 Antidiabetic Biguanides Industry Drivers
  3. 2.3 Antidiabetic Biguanides Industry Opportunities and Challenges
  4. 2.4 Antidiabetic Biguanides Industry Restraints
3 Antidiabetic Biguanides Market by Company
  1. 3.1 Global Antidiabetic Biguanides Company Revenue Ranking in 2025
  2. 3.2 Global Antidiabetic Biguanides Revenue by Company (2021-2026)
  3. 3.3 Global Antidiabetic Biguanides Sales Volume by Company (2021-2026)
  4. 3.4 Global Antidiabetic Biguanides Average Price by Company (2021-2026)
  5. 3.5 Global Antidiabetic Biguanides Company Ranking (2024-2026)
  6. 3.6 Global Antidiabetic Biguanides Company Manufacturing Base and Headquarters
  7. 3.7 Global Antidiabetic Biguanides Company Product Type and Application
  8. 3.8 Global Antidiabetic Biguanides Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antidiabetic Biguanides Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antidiabetic Biguanides Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antidiabetic Biguanides Market by Type
  1. 4.1 Antidiabetic Biguanides Type Introduction
  2. 4.1.1 Metformin IR
  3. 4.1.2 Metformin SR
  4. 4.2 Global Antidiabetic Biguanides Sales Volume by Type
  5. 4.2.1 Global Antidiabetic Biguanides Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antidiabetic Biguanides Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antidiabetic Biguanides Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antidiabetic Biguanides Sales Value by Type
  9. 4.3.1 Global Antidiabetic Biguanides Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antidiabetic Biguanides Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antidiabetic Biguanides Sales Value Share by Type (2021-2032)
5 Antidiabetic Biguanides Market by Application
  1. 5.1 Antidiabetic Biguanides Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic Biguanides Sales Volume by Application
  6. 5.2.1 Global Antidiabetic Biguanides Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic Biguanides Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Antidiabetic Biguanides Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Antidiabetic Biguanides Sales Value by Application
  10. 5.3.1 Global Antidiabetic Biguanides Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antidiabetic Biguanides Sales Value by Application (2021-2032)
  12. 5.3.3 Global Antidiabetic Biguanides Sales Value Share by Application (2021-2032)
6 Antidiabetic Biguanides Regional Sales and Value Analysis
  1. 6.1 Global Antidiabetic Biguanides Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic Biguanides Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic Biguanides Sales by Region: 2021-2026
  4. 6.2.2 Global Antidiabetic Biguanides Sales by Region (2027-2032)
  5. 6.3 Global Antidiabetic Biguanides Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antidiabetic Biguanides Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antidiabetic Biguanides Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antidiabetic Biguanides Sales Value by Region (2027-2032)
  9. 6.5 Global Antidiabetic Biguanides Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antidiabetic Biguanides Sales Value (2021-2032)
  12. 6.6.2 North America Antidiabetic Biguanides Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antidiabetic Biguanides Sales Value (2021-2032)
  15. 6.7.2 Europe Antidiabetic Biguanides Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antidiabetic Biguanides Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antidiabetic Biguanides Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antidiabetic Biguanides Sales Value (2021-2032)
  21. 6.9.2 South America Antidiabetic Biguanides Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antidiabetic Biguanides Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antidiabetic Biguanides Sales Value Share by Country, 2025 VS 2032
7 Antidiabetic Biguanides Country-level Sales and Value Analysis
  1. 7.1 Global Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antidiabetic Biguanides Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antidiabetic Biguanides Sales by Country (2021-2032)
  4. 7.3.1 Global Antidiabetic Biguanides Sales by Country (2021-2026)
  5. 7.3.2 Global Antidiabetic Biguanides Sales by Country (2027-2032)
  6. 7.4 Global Antidiabetic Biguanides Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antidiabetic Biguanides Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antidiabetic Biguanides Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antidiabetic Biguanides Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antidiabetic Biguanides Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antidiabetic Biguanides Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Antidiabetic Biguanides Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Servier Laboratories
  20. 8.4.1 Servier Laboratories Company Information
  21. 8.4.2 Servier Laboratories Business Overview
  22. 8.4.3 Servier Laboratories Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Servier Laboratories Antidiabetic Biguanides Product Portfolio
  24. 8.4.5 Servier Laboratories Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Antidiabetic Biguanides Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antidiabetic Biguanides Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Antidiabetic Biguanides Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Antidiabetic Biguanides Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Merck & Co
  50. 8.9.1 Merck & Co Company Information
  51. 8.9.2 Merck & Co Business Overview
  52. 8.9.3 Merck & Co Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co Antidiabetic Biguanides Product Portfolio
  54. 8.9.5 Merck & Co Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Antidiabetic Biguanides Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Takeda Pharmaceuticals
  62. 8.11.1 Takeda Pharmaceuticals Company Information
  63. 8.11.2 Takeda Pharmaceuticals Business Overview
  64. 8.11.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio
  66. 8.11.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic Biguanides Value Chain Analysis
  2. 9.1.1 Antidiabetic Biguanides Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic Biguanides Sales Mode & Process
  6. 9.2 Antidiabetic Biguanides Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic Biguanides Distributors
  9. 9.2.3 Antidiabetic Biguanides Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst